Safety and immunogenicity of heterologous prime-boost immunisation with plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan Adults

Gregson, Aric, Ogwang, Caroline, Afolabi, Muhammed, Kimani, Domtila, Jagne, Ya Jankey, Sheehy, Susanne H., Bliss, Carly M., Duncan, Christopher J. A., Collins, Katharine A., Garcia Knight, Miguel A., Kimani, Eva, Anagnostou, Nicholas A., Berrie, Eleanor, Moyle, Sarah, Gilbert, Sarah C., Spencer, Alexandra J., Soipei, Peninah, Mueller, Jenny, Okebe, Joseph, Colloca, Stefano, Cortese, Riccardo, Viebig, Nicola K., Roberts, Rachel, Gantlett, Katherine, Lawrie, Alison M., Nicosia, Alfredo, Imoukhuede, Egeruan B., Bejon, Philip, Urban, Britta C., Flanagan, Katie L., Ewer, Katie J., Chilengi, Roma, Hill, Adrian V. S. and Bojang, Kalifa 2013. Safety and immunogenicity of heterologous prime-boost immunisation with plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan Adults. PLoS ONE 8 (3) , e57726. 10.1371/journal.pone.0057726

PDF - Published Version Available under License Creative Commons Attribution. Download (872kB)

Abstract

Background Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI). Methodology We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns. Results ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC). Conclusions ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Public Library of Science
ISSN:	1932-6203
Date of First Compliant Deposit:	6 January 2021
Date of Acceptance:	24 January 2013
Last Modified:	07 May 2023 21:11
URI:	https://orca.cardiff.ac.uk/id/eprint/137207

Citation Data

Cited 61 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item